NCT02623829View on ClinicalTrials.gov

Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions
Post-operative Excessive Scarring
Interventions
DRUG

Botulinum Toxin

50 units of botulinum toxin diluted in 1ml of normal saline will be administered.

DRUG

Saline

1ml of normal saline will be administered

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinia, New York

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER